CD19 and neoplasm: A study by Chen Y. et al. found that the combination of chemotherapy with an anti-BTLA antibody that inhibits IL-6/IL-10-induced CD19-high B-lymphocytes significantly reduced peritoneal tumor volume and prolonged the survival time of mice with epithelial ovarian carcinoma [51].